Value proposition

Acquired by Evotec SE in July 2022, Rigenerand is now operating as Evotec (Moderna) Srl.

Originating as a start-up from the University of Modena and Reggio Emilia developing and producing innovative products for pre-clinical and clinical applications of cell-based technologies for regenerative medicine and oncology, the cell technology company aims to fill therapeutic gaps for the many still incurable diseases by manufacturing smart treatments based on gene-modified cells with a specific focus on cancer

With its team of leading cell therapy experts, Evotec (Moderna) adds a high-quality cGMP manufacturing site to the EVOcells platform increasing capacity, critical expertise, and capabilities to the scale-up of complex cell-based therapies.

Medical Devices, 3D Culture Systems, Cancer, Regenerative Medicine, Precision Medicine, 3D Diagnostics, Cell Therapy, Gene Therapy, cGMP Facility, and Cell Factory